USABiotech & Genomic Medicine▲
Non-Muscle Invasive Bladder Cancer Market to Shift as Novel Therapies Enter Late-Stage Development
The non-muscle invasive bladder cancer market is expected to undergo significant transformation during the 2026 to 2036 forecast period as novel targeted and gene therapies advance through late-stage clinical development. The total market size across the seven major markets, comprising the United States, the EU4 countries of Germany, France, Italy, and Spain, the United Kingdom, and Japan, was approximately USD 3 billion in 2025, with the United States holding the largest share. Total prevalent cases of non-muscle invasive bladder cancer in these markets were nearly 1.56 million and are projected to increase by 2036. Key emerging therapies include CG0070 from CG Oncology, EG-70 from enGene, TAR-210 from Janssen, Dabogratinib from Tyra Biosciences, UGN-103 from UroGen Pharma, and TARA-002 from Protara Therapeutics, with cretostimogene grenadenorepvec plus or minus KEYTRUDA expected to generate the highest revenue among all therapies by 2036.
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
Biotech & Genomic Medicine › Gene & Cell Editing ▲Technology
CGON · Technology · Positive CG0070 from CG Oncology is highlighted as a key emerging therapy expected to generate highest revenue by 2036.
TARA · Technology · Positive TARA-002 from Protara Therapeutics is listed as a key emerging therapy in late-stage development.
TYRA · Technology · Positive Dabogratinib from Tyra Biosciences is listed as a key emerging therapy in late-stage development.
URGN · Technology · Positive UGN-103 from UroGen Pharma is listed as a key emerging therapy in late-stage development.